Company Overview and News


Add PTLA
to your dashboard

Headline News

4th-Quarter 2017 Portfolio Review And Price Increase For Integrated BioScI Investing

2018-01-11 seekingalpha
Since the Kite Pharma acquisition, other stellar performers continued to procure gargantuan profits, including Nektar, Amicus, Spectrum, and Alpine (following by the substantial winnings from new portfolio additions). (132-3)

Trump's tax law could spur pharmaceutical M&A deals this year

2018-01-08 cnbc
Celgene's acquisition of Impact Biomedicines could be just the start of a flurry of deals in the pharmaceuticals world. (13-0)

Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results

2018-01-03 seekingalpha
Today we will discuss the latest update from Achaogen (AKAO). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market. According to Blake Wise, Achaogen’s CEO, the number of confirmed cases of CRE annually in the U.S. alone total at least 70,000. More important, Wise noted is that the number is projected to double by 2022. (224-6)

Biotech Forum Daily Digest: Why We Are Passing On Pulse

2017-12-29 seekingalpha
The biotech sector looks poised to end 2017 up a little more than 20% on the year despite a dearth of M&A activity across the industry. (160-0)

Top Analyst Upgrades and Downgrades: American Water Works, JB Hunt, Ford, GM, AstraZeneca and More

2017-12-29 247wallst
Stocks hit all-time highs many times during 2017, and the last trading day of the year seems to be off to a strong start. The Dow Jones Industrial Average is up about 25% and the S&P 500 is up about 20%, if you include dividends. Now investors have to weigh what will come to pass in 2018, noting that they have been rewarded over and over for buying the dips at the same time that the bull market is almost nine years old. (212-0)

Biotech Forum Daily Digest: Behind Fate's Rally

2017-12-26 seekingalpha
Biotech ended the previous weak, a bit better than flat thanks to big upsurge in the small cap part of the sector on Friday. (317-1)

Portola's (PTLA) AndexXa BLA Review Period Extended by FDA

2017-12-26 zacks
Portola Pharmaceuticals, Inc. (PTLA - Free Report) announced that the FDA has extended the review period of its biologics license application (BLA) for the reversal agent of Factor Xa inhibitors, AndexXa (andexanet alfa), by 90 days. As a result, the regulatory body will now announce its decision by May 4, 2018 instead of the previously set deadline of Feb 3, 2018. (57-0)

Portola Pharmaceuticals: What The AndexXa Approval Delay Means?

2017-12-24 seekingalpha
The US FDA recently approved the Prior Approval Supplement for Bevyxxa in advance of the anticipated date. (12-0)

BRIEF-Portola Pharma Says FDA will extend review of AndexXa by 90 days

2017-12-22 reuters
* PORTOLA PHARMACEUTICALS - U.S. FDA WILL EXTEND REVIEW OF BIOLOGICS LICENSE APPLICATION FOR ANDEXXA (ANDEXANET ALFA) BY 90 DAYS Source text for Eikon: Further company coverage: (11-0)

Portola Pharmaceuticals: What The Early FDA Approval Of Bevyxxa PAS Entails

2017-12-22 seekingalpha
US-FDA approved the Prior Approval Supplement of Bevyxxa in advance of its Jan 30, 2018, date. (12-0)

Biotech Forum Daily Digest: Aerie Pharmaceuticals Garners Early FDA Approval

2017-12-20 seekingalpha
The biotech sector is set to wrap up a solid year in 2017.  Tax reform could spark a noticeable uptick in M&A in 2018. (42-0)

CytomX Therapeutics: A Possible ASCO Runner For Next Year

2017-12-19 seekingalpha
Upside in the medium term could come from several clinical readouts throughout 2018 (ASCO and ESMO). (82-2)

BRIEF-U.S. FDA Approves Prior Approval Supplement For Launch Of Portola Pharmaceuticals' Betrixaban

2017-12-19 reuters
* U.S. FOOD AND DRUG ADMINISTRATION APPROVES PRIOR APPROVAL SUPPLEMENT FOR COMMERCIAL LAUNCH OF PORTOLA PHARMACEUTICALS’ NOVEL ORAL ANTICOAGULANT BEVYXXA® (BETRIXABAN) (11-0)

Portola Pharma Wins With FDA Approval

2017-12-19 247wallst
Portola Pharmaceuticals Inc. (NASDAQ: PTLA) shares saw a handy gain on Tuesday after the company announced that it received a key approval from the U.S. Food and Drug Administration (FDA). Specifically, the FDA approved the company’s Prior Approval Supplement (PAS) for Bevyxxa (betrixaban) ahead of its scheduled January 30 action date, allowing for the release and distribution of its current product inventory. (11-0)

ROTY Edition 1 Volume 64: Several Key Updates And Trades

2017-12-19 seekingalpha
While performance for December continues to disappoint, we continue to position the ROTY model account for a profitable 2018. (471-1)

CUSIP: 737010108